Added to YB: 2025-12-13
Pitch date: 2025-12-11
MEDCL.PA [bullish]
MedinCell S.A.
-18.24%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France.
Market Cap
EUR 879.8M
Pitch Price
EUR 29.50
Price Target
N/A
Dividend
N/A
EV/EBITDA
-44.97
P/E
-26.06
EV/Sales
35.71
Sector
Pharmaceuticals
Category
growth
Medincell (MEDCL France): execution on track as UZEDY gains traction and pipeline advances
MEDCL.PA (update): LAI platform gaining traction with UZEDY royalties driving 35% revenue growth to €11.6M. Teva expects $190-200M UZEDY sales 2025, olanzapine FDA submission accepted for 10-month review. Strong phase III safety data, no post-injection issues. €53.5M cash runway through milestones.
Read full article (2 min)